Geraniol produces antidepressant-like effects in a chronic unpredictable mild stress mice model

Physiology and Behavior

Volumn 152, Issue , 2015, Pages 264-271

  Deng, Xue Yang ^a   Xue, Jin Song ^a   Li, Hong Yan ^a   Ma, Zhan Qiang ^a   Fu, Qiang ^a   Qu, Rong ^b   Ma, Shi Ping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Antidepressant; Geraniol; Neuro inflammation; NF B; NLRP3

Indexed keywords

FLUOXETINE; GERANIOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; ANTIDEPRESSANT AGENT; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; CORTICOSTERONE; IL1B PROTEIN, MOUSE; INFLAMMASOME; INTERLEUKIN 1BETA CONVERTING ENZYME; TERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHRONIC UNPREDICTABLE MILD STRESS; CHRONIC UNPREDICTABLE STRESS; CONTROLLED STUDY; DEPRESSION; FOOD DEPRIVATION; FORCED SWIM TEST; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; SUCROSE PREFERENCE TEST; TAIL SUSPENSION TEST; ANIMAL; BLOOD; CHRONIC DISEASE; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; IMMUNOMODULATION; INSTITUTE FOR CANCER RESEARCH MOUSE; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREFRONTAL CORTEX; UNCERTAINTY;

ANIMALS; ANTIDEPRESSIVE AGENTS; CARRIER PROTEINS; CASPASE 1; CHRONIC DISEASE; CORTICOSTERONE; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; FLUOXETINE; INFLAMMASOMES; INTERLEUKIN-1BETA; MALE; MICE, INBRED ICR; NEUROIMMUNOMODULATION; NF-KAPPA B; PREFRONTAL CORTEX; STRESS, PSYCHOLOGICAL; TERPENES; UNCERTAINTY;

EID: 84944892881     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2015.10.008     Document Type: Article

References (45)

1. Sartorius N. The economic and social burden of depression. J. Clin. Psychiatry 2001, 62:8-11.
2. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349:1498-1504.
3. Meyer J.H., Ginovart N., Boovariwala A., et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry 2006, 63:1209-1216.
4. Kennedy S.H., Andersen H.F., Thase M.E. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr. Med. Res. Opin. 2008, 25:161-175.
5. Gartlehner G., Thieda P., Hansen R., Gaynes B., DeVeaugh-Geiss A., Krebs E., et al. Comparative risk for harms of second generation antidepressants. Drug Saf. 2008, 31:851-865.
6. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35:664-675.
7. Gadek-Michalska A., Tadeusz J., Rachwalska P., Bugajski J. Cytokines, prostaglandins and nitric oxide in the regulation of stress-response systems. Pharmacol. Rep. 2013, 65:1655-1662.
8. Schroder K., Zhou R., Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger?. Science 2010, 327:296-300.
9. Bauernfeind F.G., Horvath G., Stutz A., Alnemri E.S., MacDonald K., Speert D., et al. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 2009, 183:787-791.
10. Di Virgilio F. The therapeutic potential of modifying inflammasomes and NOD-like receptors. Pharmacol. Rev. 2013, 65:872-905.
11. Quan W., Jo E.K., Lee M.S. Role of pancreatic β-cell death and inflammation in diabetes. Diabetes Obes. Metab. 2013, 15:141-151.
12. Lu M., Yang J.-Z., Geng F., Ding J.-H., Hu G. Iptakalim confers an antidepressant effect in a chronic mild stress model of depression through regulating neuro-inflammation and neurogenesis. Int. J. Neuropsychopharmacol. 2014, 17:1501-1510.
13. Pahin C., Arýcýodlu F. A novel aspect for depression and cytokine hypothesis: NLRP3 inflammasome. MÜSBED 2013, 3:65-68.
14. Lapczynski A., Bhatia S.P., Foxenberg R.J., Letizia C.S., Api A.M. Fragrance material review on geraniol. Food Chem. Toxicol. 2008, 46(Suppl. 11):160-170.
15. Medicherla K., Sahu B.D., Kuncha M., Kumar J.M., Sudhakar G., Sistla R. Oral administration of geraniol ameliorates acute experimental murine colitis by inhibiting pro-inflammatory cytokines and NF-kappa B signaling. Food. Funct. 2015, 6:2984-2995.
16. Vinothkumar V., Manoharan S., Sindhu G., Nirmal M.R., Vetrichelvi V. Geraniol modulates cell proliferation, apoptosis, inflammation, and angiogenesis during 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. Mol. Cell. Biochem. 2012, 369:17-25.
17. Su Y.W., Chao S.H., Lee M.H., Ou T.Y., Tsai Y.C. Inhibitory effects of citronellol and geraniol on nitric oxide and prostaglandin E(2)production in macrophages. Planta Med. 2010, 76:1666-1671.
18. Khan A.Q., Khan R., Qamar W., Lateef A., Rehman M.U., Tahir M., et al. Geraniol attenuates 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced oxidative stress and inflammation in mouse skin: possible role of p38 MAP kinase and NF-kappa B. Exp. Mol. Pathol. 2013, 94:419-429.
19. Buch P., Patel V., Ranpariya V., Sheth N., Parmar S. Neuroprotective activity of Cymbopogon martinii against cerebral ischemia/reperfusion-induced oxidative stress in rats. J. Ethnopharmacol. 2012, 142:35-40.
20. Prasad Sathya N., Muralidhara Neuroprotective effect of geraniol and curcumin in an acrylamide model of neurotoxicity in Drosophila melanogaster: relevance to neuropathy. J. Insect Physiol. 2014, 60:7-16.
21. Rekha K.R., Selvakumar G.P., Sethupathy S., Santha K., Sivakamasundari R.I. Geraniol ameliorates the motor behavior and neurotrophic factors inadequacy in MPTP-induced mice model of Parkinson's disease. J. Mol. Neurosci. 2013, 51:851-862.
22. Rekha K.R., Selvakumar G.P., Santha K., Sivakamasundari R.I. Geraniol attenuates alpha-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner. Biochem. Biophys. Res. Commun. 2013, 440:664-670.
23. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 1987, 93:358-364.
24. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229:327-336.
25. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
26. Frankel A.I., Cook B., Graber J.W., Nalbandov A.V. Determination of corticosterone in plasma by fluorometric techniques. Endocrinology 1967, 80:181-194.
27. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 1997, 134:319-329.
28. Cryan J.F., Valentino R.J., Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev. 2005, 29:547-569.
29. Li S., Wang C., Wang M., Li W., Matsumoto K., Tang Y. Antidepressant like effects of piperine in chronic mild stress treated mice and its possible mechanisms. Life Sci. 2007, 80:1373-1381.
30. Yalcin I., Belzung C., Surget A. Mouse strain differences in the unpredictable chronic mild stress: a four-antidepressant survey. Behav. Brain Res. 2008, 193:140-143.
31. Pothion S., Bizot J.-C., Trovero F., Belzung C. Strain differences in sucrose preference and in the consequences of unpredictable chronic mild stress. Behav. Brain Res. 2004, 155:135-146.
32. Mutlu O., Ulak G., Laugeray A., Belzung C. Effects of neuronal and inducible NOS inhibitor 1-[2-(trifluoromethyl) phenyl] imidazole (TRIM) in unpredictable chronic mild stress procedure in mice. Pharmacol. Biochem. Behav. 2009, 92:82-87.
33. McArthur R., Borsini F. Animal models of depression in drug discovery: a historical perspective. Pharmacol. Biochem. Behav. 2006, 84:436-452.
34. Evans J., Sun Y., McGregor A., Connor B. Allopregnanolone regulates neurogenesis and depressive/anxiety-like behaviour in a social isolation rodent model of chronic stress. Neuropharmacology 2012, 63:1315-1326.
35. Nadjar A., Bluthe R.-M., May M.J., Dantzer R., Parnet P. Inactivation of the cerebral NF[kappa]B pathway inhibits interleukin-1[beta]-induced sickness behavior and c-Fos expression in various brain nuclei. Neuropsychopharmacology 2005, 30:1492-1499.
36. Zhang Y., Liu L., Peng Y.L., Liu Y.Z., Wu T.Y., Shen X.L., et al. Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors. CNS Neurosci. Ther. 2014, 20:119-124.
37. Pan Y., Chen X.-Y., Zhang Q.-Y., Kong L.-D. Microglial NLRP3 inflammasome activation mediates IL-1β-related inflammation in prefrontal cortex of depressive rats. Brain Behav. Immun. 2014, 41:90-100.
38. Alcocer-Gómez E., de Miguel M., Casas-Barquero N., Núñez-Vasco J., Sánchez-Alcazar J.A., Fernández-Rodríguez A., et al. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav. Immun. 2014, 36:111-117.
39. Sahin C., Aricioglu F. Future directions of cytokine hypothesis in depression: 'NLRP3 inflammasome'. Bull. Clin. Psychopharmacol. 2013, 23:280-288.
40. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008, 31:464-468.
41. Pace T.W.W., Hu F., Miller A.H. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav. Immun. 2007, 21:9-19.
42. Busillo J.M., Azzam K.M., Cidlowski J.A. Glucocorticoids sensitize the innate immune system through regulation of the NLRP3 inflammasome. J. Biol. Chem. 2011, 286:38703-38713.
43. Sinha S., Jothiramajayam M., Ghosh M., Mukherjee A. Evaluation of toxicity of essential oils palmarosa, citronella, lemongrass and vetiver in human lymphocytes. Food Chem. Toxicol. 2014, 68:71-77.
44. Boukhatem M.N., Kameli A., Ferhat M.A., Saidi F., Mekarnia M. Rose geranium essential oil as a source of new and safe anti-inflammatory drugs. Libyan J. Med. 2013, 8. 10.3402/ljm.v3408i3400.22520.
45. Jayachandran M., Chandrasekaran B., Namasiyayam N. Geraniol attenuates fibrosis and exerts anti-inflammatory effects on diet induced atherogenesis by NF-kappa B signaling pathway. Eur. J. Pharmacol. 2015, 762:102-111.